Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Medtronic
UBS
Teva
Covington
Merck

Generated: August 17, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,632,981

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,632,981
Title:Process of producing environmentally safe transgenic organisms
Abstract: A process of producing a transgenic multi-cellular plant or animal organism expressing a trait of interest and having a controlled distribution of said trait to progeny, wherein said process comprises hybridising a first multi-cellular organism or a cell thereof having a first heterologous DNA sequence comprising a first fragment of a nucleotide sequence encoding said trait of interest and a second multi-cellular organism or a cell thereof having a second heterologous DNA sequence comprising a second fragment of the nucleotide sequence encoding said trait of interest, whereby said first and said second heterologous sequences are designed such that said trait of interest arises due to RNA trans-splicing after said hybridation.
Inventor(s): Werner; Stefan (Halle/Saale, DE), Marillonnet; Sylvestre (Halle/Saale, DE), Klimyuk; Victor (Halle/Saale, DE), Gleba; Yuri (Halle/Saale, DE)
Assignee: Icon Genetics GmbH (Munich, DE)
Application Number:10/512,879
Patent Claims:1. A process of producing a transgenic multi-cellular plant organism expressing a trait of interest and having a controlled distribution of said trait to progeny, wherein said process comprises sexual crossing of a first multi-cellular plant organism having a first heterologous DNA sequence comprising a first fragment of a nucleotide sequence conferring said trait of interest and a second multi-cellular plant organism having a second heterologous DNA sequence comprising a second fragment of the nucleotide sequence conferring said trait of interest, wherein at least one of said first and said second heterologous DNA sequences encodes a ribozyme for trans-splicing, and wherein the trans-splicing ribozyme is a Tetrahymena thermophila 26S rRNA, group I intron-derived ribozyme, whereby said first and said second heterologous sequences are designed such that said trait of interest arises due to RNA trans-splicing after said sexual crossing, and whereby said first and said second fragment of a nucleotide sequence conferring said trait of interest are present on allelic chromosomes, wherein said first and/or said second heterologous sequence contains an intron or a part thereof such that the RNA product of the trans-splicing reaction contains an intron capable of cis-splicing.

2. The process according to claim 1, wherein said controlled distribution means that, upon crossing of said transgenic multi-cellular organism with an organism devoid of said first and said second heterologous sequences, the frequency of the appearance of said trait in descendent organisms is less than 1%.

3. The process according to claim 1, wherein said transgenic multi-cellular plant is incapable of expressing said trait of interest in the absence of either said first or said second heterologous sequence.

4. The process according to claim 1, wherein said trans-splicing results in messenger RNA capable of translating and producing a protein, thus endowing said transgenic multi-cellular plant organism with said trait of interest.

5. The process according to claim 1, wherein said trans-splicing results in a plurality of expressible messenger RNAs, thus generating multiple proteins or different chimeric proteins.

6. The process according to claim 1, wherein said multi-cellular organism is provided with said first or said second heterologous sequence by viral transfection, Agrobacterium-mediated delivery, non-biological delivery, or by conversion of (a) polynucleotide molecule(s) that was pre-integrated into a nuclear DNA or was maintained in the nucleus autonomously, to form said first or said second heterologous sequence.

7. The process according to claim 6, comprising stable transformation and stable integration of said first and/or said second heterologous sequence into a chromosome of said multi-cellular organism.

8. The process according to claim 1, wherein said multi-cellular organism is further genetically or transiently modified for providing functions necessary for said trans-splicing and/or said expressing of the trait of interest.

9. The process according to claim 1, wherein said first and/or said second fragment is operably linked to more than one nucleic acid encoding more than one trans-splicing ribozyme or to two or more different trans-splicing ribozymes.

10. The process according to claim 1, wherein said trait of interest is involved in male sterility.

11. The process according to claim 1, wherein said trait is selected from the group consisting of herbicide resistance, insect resistance, a selectable marker, and a counter-selectable marker.

12. The process according to claim 1, wherein expression of said trait of interest depends on the correct processing of said first and/or said second heterologous sequence(s).

13. The process according to claim 1, wherein said first and said second heterologous sequences in said transgenic multi-cellular plant organism segregate as unlinked loci.

14. The process according to claim 13, wherein said unlinked loci are positioned so as to minimize recombination and creation of linkage between said loci.

15. The process according to claim 1, wherein said first and said second heterologous sequences in said transgenic multi-cellular plant organism are located in the same locus on said allelic chromosomes.

16. The process according to claim 1, wherein the trans-splicing reaction and translation of the product of said trans-splicing reaction generates a protein having a polypeptide linked thereto by said trans-splicing reaction, whereby said polypeptide is selected from the group consisting of signalling, targeting, and membrane transduction polypeptides, and recognition and purification tags.

17. The process according to claim 1, wherein said transgenic multi-cellular organism is capable of producing progeny.

18. The process according to claim 1, wherein said first multi-cellular organism is made homozygous with respect to said first heterologous DNA sequence and said second multi-cellular organism is made homozygous with respect to said second heterologous DNA sequence.

19. The process according to claim 1, wherein said process is used for producing hybrid seeds of said transgenic multi-cellular plant.

20. A transgenic multi-cellular plant organism expressing a trait of interest, said organism having a controlled distribution of said trait to progeny, wherein expression of said trait involves production of an RNA molecule by trans-splicing of RNA fragments, wherein said multi-cellular plant organism has a first heterologous DNA sequence and a second heterologous DNA sequence, said first heterologous DNA sequence comprising a first fragment of a nucleotide sequence conferring said trait of interest and said second heterologous DNA sequence comprising a second fragment of the nucleotide sequence conferring said trait of interest, wherein at least one of said first and said second heterologous DNA sequences encodes a ribozyme for trans-splicing, and wherein the trans-splicing ribozyme is a Tetrahymena thermophila 26S rRNA, group I intron-derived ribozyme, whereby said first and said second heterologous sequences are designed such that said trait of interest arises due to RNA trans-splicing, whereby said first and said second fragment of a nucleotide sequence conferring said trait of interest are present on allelic chromosomes, and wherein said first and/or said second heterologous sequence contains an intron or a part thereof such that the RNA molecule contains an intron capable of cis-splicing.

Summary for Patent:   Try a Free Trial

PCT Information
PCT FiledApril 29, 2002PCT Application Number:PCT/EP02/04724
PCT Publication Date:December 05, 2002PCT Publication Number:WO02/096192

Details for Patent 7,632,981

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial Icon Genetics GmbH (Munich, DE) 2037-11-11 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial Icon Genetics GmbH (Munich, DE) 2037-11-11 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial Icon Genetics GmbH (Munich, DE) 2037-11-11 RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chinese Patent Office
Johnson and Johnson
Citi
Healthtrust
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.